1-甲基-4-苯基-1H-吡咯-3-羧酸乙酯 | 131911-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 1-甲基-4-苯基-1H-吡咯-3-羧酸乙酯
• 英文名称: ethyl 1-methyl-4-phenyl-1H-pyrrole-3-carboxylate
• 英文别名: Ethyl 1-methyl-4-phenylpyrrole-3-carboxylate
• CAS: 131911-14-3
• 化学式: C₁₄H₁₅NO₂
• 分子量: 229.279
• InChiKey: FPSHOBNKMVAAGI-UHFFFAOYSA-N

物化性质

• 熔点：
  56-57 °C(Solv: cyclohexane (110-82-7))
• 沸点：
  377.6±35.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-甲基-4-苯基-1H-吡咯-3-羧酸乙酯 在 sodium hydroxide 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 1-Methyl-4-phenyl-1H-pyrrole-3-carboxylic acid methyl-naphthalen-1-ylmethyl-amide
  参考文献：
  名称：

  Di Santo, Roberto; Costi, Roberta; Artico, Marino, Medicinal Chemistry Research, 1997, vol. 7, # 2, p. 98 - 108

  摘要：

  DOI：
• 作为产物：
  描述：

  肉桂酸乙酯 在 sodium hydride 、 potassium carbonate 作用下， 以 乙醚 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1-甲基-4-苯基-1H-吡咯-3-羧酸乙酯
  参考文献：
  名称：

  Massa; Di Santo; Mai, Il Farmaco, 1990, vol. 45, # 7-8, p. 833 - 846

  摘要：

  DOI：

文献信息

• Solvent-Controlled Switchable C–H Alkenylation of 4-Aryl-1<i>H</i>-pyrrole-3-carboxylates: Application to the Total Synthesis of (±)-Rhazinilam
  作者：Youla Su、Haipin Zhou、Jiaxuan Chen、Jinyi Xu、Xiaoming Wu、Aijun Lin、Hequan Yao

  DOI：10.1021/ol5023933

  日期：2014.9.19

  A solvent-controlled switchable C–H alkenylation of 4-aryl-1H-pyrrole-3-carboxylates via a Pd(OAc)2 catalyzed oxidative Heck reaction was first realized. The corresponding C2 and C5 alkenylation products were obtained in good yields with high regioselectivities, respectively. The selective C5-alkenylation was successfully applied to the total synthesis of (±)-rhazinilam.

  首先通过Pd（OAc）2催化的氧化Heck反应实现了溶剂控制的4-芳基1 H-吡咯-3-羧酸酯的C-H链烯基化反应。分别以高收率和高区域选择性获得了相应的C2和C5烯基化产物。选择性的C5-烯基化成功地应用于（±）-rhazinilam的全合成。
• Differential reactivity of β-amino enones and 3-dimethylaminoacrylaldehyde towards α-amino derivatives
  作者：Angel Alberola、José M. Andrés、Alfonso González、Rafael Pedrosa、Martina Vicente

  DOI：10.1039/p19900002681

  日期：——

  Unsubstituted β-amino enones react with α-amino derivatives by a well established route which implies a fast transamination process — 1,4-addition followed by elimination — and cyclodehydration of the intermediate to 3-functionalized pyrroles. In contrast, 3-dimethylaminoacrylaldehyde undergoes 1,2-addition followed by cyclization to give the final 2-substituted pyrroles. Isolation of the intermediates

  未取代的β-氨基烯酮通过一种完善的途径与α-氨基衍生物反应，这意味着快速的氨基转移过程-1,4-加成，然后消除-并将中间体环脱水为3-官能化的吡咯。相反，使3-二甲基氨基丙烯醛进行1，2-加成，然后环化，得到最终的2-取代的吡咯。中间体的分离为每种反应提供了建议的机理。
• [EN] NOVEL VIRAL REPLICATION INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE LA RÉPLICATION VIRALE
  申请人：UNIV LEUVEN KATH

  公开号：WO2014154682A1

  公开（公告）日：2014-10-02

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，用于预防或治疗动物病毒感染的方法，以及用于作为药物的这些新化合物，更好地用于治疗或预防病毒感染，特别是感染RNA病毒，更具体地是属于黄病毒科家族的病毒感染，更具体地是登革病毒感染。本发明还涉及新化合物的药物组合或混合制剂，用于作为药物的组合或制剂，更好地用于预防或治疗病毒感染。该发明还涉及化合物的制备方法。
• Viral replication inhibitors
  申请人：KATHOLIEKE UNIVERSITEIT LEUVEN

  公开号：US10633378B2

  公开（公告）日：2020-04-28

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新型化合物、使用这些新型化合物预防或治疗动物病毒感染的方法以及用作药物的所述新型化合物，更优选用作治疗或预防病毒感染的药物，特别是 RNA 病毒感染，更特别是属于黄病毒科的病毒感染，更特别是登革热病毒感染。本发明还涉及新型化合物的药物组合物或组合制剂、用作药物的组合物或制剂，更优选用于预防或治疗病毒感染。本发明还涉及化合物的制备工艺。
• MASSA, SILVIO;DI, SANTO ROBERTO;MAI, ANTONELLO;BOTTA, MAURIZIO;ARTICO, MA+, FARMACO., 45,(1990) N-8, C. 833-846
  作者：MASSA, SILVIO、DI, SANTO ROBERTO、MAI, ANTONELLO、BOTTA, MAURIZIO、ARTICO, MA+

  DOI：——

  日期：——